In a recent international vitamin D seminar held in Mumbai, a call-to-action was raised as the prevalence of vitamin D deficiency in India reaches nearly 80%. Over 1,000 physicians, gynecologists, pediatricians, orthopedists, cardiologists and endocrinologists joined this seminar in early August.
Dr. Bruce Hollis, vitamin D expert, attended as a speaker at the Recent Advancements in Vitamin D Therapy Management conference. Due to the major prevalence of vitamin D deficiency in India and the adverse complications it’s been associated with, Dr. Hollis called for a spread in awareness and treatment in deficiency.
He appealed mainly to the maternal population, as correcting gestational vitamin D deficiency may solve many of the health problems present in India. He stressed the importance of correcting vitamin D deficiency during pregnancy due to its role in gestational diabetes, preeclampsia, asthma risk and more. According to research, at least 4,000 IU vitamin D3 is required to reduce pregnancy and birth complications. Additionally, further studies have suggested 6,400 IU vitamin D3 is required during breastfeeding to provide the infant with adequate vitamin D through the mother’s breast milk.
Additionally, there is a high prevalence of vitamin D deficiency in the general Indian population, which must be corrected.
Dr. Hollis stated:
“If not managed on priority, a large population of Indians, including infants, suffering from Vitamin D deficiency, run a huge risk of suffering from rickets, osteoporosis, cardiovascular diseases, diabetes, cancer and infections such as tuberculosis.”
Several medical professionals echoed Dr. Hollis’s concerns for vitamin D adequacy in India. Dr. Ebnezar, an internationally renowned Orthopedician, Spine and Geriatric Surgeon from Bengaluru stated, “Vitamin D deficiency is quite common in my practice and levels of Vitamin D are very low in Indian population. It is imperative that people get adequate awareness.”
For more information on the conference, please contact:
Mukund Trivedy / Susim Mohanty
Cadila Pharmaceuticals Ltd
Cell: 7573032251 /9825413030